Back

PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?

European Heart Journal

14 January 2022
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY HEART FAILURE Chronic Heart Failure BASIC SCIENCE Pharmacology and Pharmacotherapy

Contributors

Alexander Niessner
Alexander Niessner

Author

Heinz Drexel
Heinz Drexel

Author

Vorarlberg Institute for Vascular Investigation and Treatment Feldkirch , Austria

You may be interested in
thumbnail
Congress Presentation
Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials
28 August 2023
thumbnail
Congress Session
From genetic signatures to clinical implications
18 May 2025
thumbnail
Congress Presentation
Statin therapy in chronic heart failure with reduced ejection fraction: a post-hoc analysis of T.O.S.C.A. Registry
3 April 2025
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources